Ainos Inc

Ainos Inc(AIMD)の株式分析

$0.960

0.000 (0.00%)終値時点

Loading chart…
高値
1.030
始値
0.930
出来高加重平均価格
0.95
出来高
68.99K
時価総額
5.50M
安値
0.870
売買代金
65.78K
EV/EBITDA(TTM)
0.00

Ainos, Inc. is a dual-platform AI and biotech company advancing SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. It is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.

www.ainos.com

AI分析 of Ainos Inc (AIMD)

売り

Ainos Inc is not a good buy right now due to its poor financial performance and negative momentum indicators. The current price is $1.21, and the RSI is at 27.229, indicating oversold conditions but also suggesting continued weakness. Additionally, the forward P/E ratio is 13.9082, which is high given the company's declining revenues and increasing losses, with a 1-year change of -69.29%.

バリュエーション指標

Ainos Inc(AIMD)の現在の予想PERは13.91で、5年平均は2.25です。

予想PER

大幅な割高
5年平均 P/E
2.25
現在のP/E
13.91
割高
7.35
割安
-2.84

予想EV/EBITDA

大幅な割安
5年平均 EV/EBITDA
0.00
現在のEV/EBITDA
0.00
割高
0.00
割安
0.00

予想PSR

大幅な割安
5年平均 P/S
0.00
現在のP/S
0.00
割高
0.00
割安
0.00

Alphio AI による AIMD の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%AIMD

$3.22

シナリオ価格

基

基本

基本 · 50%AIMD

$2.84

シナリオ価格

弱

弱気

弱気 · 25%AIMD

$2.25

シナリオ価格

イベントタイムライン

2026-09-30 (ET)

10:00:00

Ainos Completes VELDONA Data Delivery, Triggers $600,000 Initial Payment

2026-09-29 (ET)

08:30:00

Ainos Completes Delivery of 1,400 AI Nose Systems to ASE

2026-09-28 (ET)

09:00:00

Ainos VELDONA License Agreement Initial Fee of $600,000

2026-09-24 (ET)

09:00:00

Ainos Enters VELDONA License Agreement with BioPhoenix, Potential Value of $10M

2026-09-14 (ET)

08:30:00

Ainos Launches Second-Gen AI Nose Platform, Secures Initial Orders

ニュース

AIMD のよくある質問 — Alphio AI が回答

Ainos, Inc. is a dual-platform AI and biotech company advancing SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. It is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ainos Inc is not a good buy right now due to its poor financial performance and negative momentum indicators. The current price is $1.21, and the RSI is at 27.229, indicating oversold conditions but also suggesting continued weakness. Additionally, the forward P/E ratio is 13.9082, which is high given the company's declining revenues and increasing losses, with a 1-year change of -69.29%.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める